Zahedan Journal of Research in Medical Sciences

Published by: Kowsar

The Beneficial Effects of Hypiran in Ameliorating Rat Model of Ulcerative Colitis

Seyyed Meysam Abtahi Froushani 1 , * and Siavash Mashouri 1
Authors Information
1 Department of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, IR Iran
Article information
  • Zahedan Journal of Research in Medical Sciences: January 2018, 20 (1); e58919
  • Published Online: January 20, 2018
  • Article Type: Research Article
  • Received: July 27, 2017
  • Revised: October 8, 2017
  • Accepted: January 14, 2018
  • DOI: 10.5812/zjrms.58919

To Cite: Abtahi Froushani S M, Mashouri S. The Beneficial Effects of Hypiran in Ameliorating Rat Model of Ulcerative Colitis, Zahedan J Res Med Sci. 2018 ; 20(1):e58919. doi: 10.5812/zjrms.58919.

Abstract
Copyright © 2018, Zahedan Journal of Research in Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Marrelli M, Statti G, Conforti F, Menichini F. New Potential Pharmaceutical Applications of Hypericum Species. Mini Rev Med Chem. 2016;16(9):710-20. [PubMed: 26156546].
  • 2. Birt DF, Widrlechner MP, Hammer KD, Hillwig ML, Wei J, Kraus GA, et al. Hypericum in infection: Identification of anti-viral and anti-inflammatory constituents. Pharm Biol. 2009;47(8):774-82. doi: 10.1080/13880200902988645. [PubMed: 19907671].
  • 3. Barnes J, Anderson LA, Phillipson JD. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2001;53(5):583-600. [PubMed: 11370698].
  • 4. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol. 2002;54(4):349-56. [PubMed: 12392581].
  • 5. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001;70(4):317-26. [PubMed: 11673747].
  • 6. Kumar V, Mdzinarishvili A, Kiewert C, Abbruscato T, Bickel U, van der Schyf CJ, et al. NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort. J Pharmacol Sci. 2006;102(1):47-54. [PubMed: 16936454].
  • 7. Cecchini C, Cresci A, Coman MM, Ricciutelli M, Sagratini G, Vittori S, et al. Antimicrobial activity of seven hypericum entities from central Italy. Planta Med. 2007;73(6):564-6. doi: 10.1055/s-2007-967198. [PubMed: 17516331].
  • 8. Josey ES, Tackett RL. St. John's wort: a new alternative for depression?. Int J Clin Pharmacol Ther. 1999;37(3):111-9. [PubMed: 10190758].
  • 9. Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Obstet Gynecol Clin North Am. 2009;36(4):789-807. x. doi: 10.1016/j.ogc.2009.10.005. [PubMed: 19944301].
  • 10. Abtahi Froushani SM, Esmaili Gouvarchin Galee H, Khamisabadi M, Lotfallahzade B. Immunomudulatory effects of hydroalcoholic extract of Hypericum perforatum. Avicenna J Phytomed. 2015;5(1):62-8. [PubMed: 25767758].
  • 11. Bork PM, Bacher S, Schmitz ML, Kaspers U, Heinrich M. Hypericin as a non-antioxidant inhibitor of NF-kappa B. Planta Med. 1999;65(4):297-300. doi: 10.1055/s-1999-13989. [PubMed: 10364831].
  • 12. Panossian AG, Gabrielian E, Manvelian V, Jurcic K, Wagner H. Immunosuppressive effects of hypericin on stimulated human leukocytes: inhibition of the arachidonic acid release, leukotriene B(4) and Interleukin-Ialpha production, and activation of nitric oxide formation. Phytomedicine. 1996;3(1):19-28. doi: 10.1016/S0944-7113(96)80005-5. [PubMed: 23194856].
  • 13. Kang BY, Chung SW, Kim TS. Inhibition of interleukin-12 production in lipopolysaccharide-activated mouse macrophages by hpyericin, an active component of Hypericum perforatum. Planta Med. 2001;67(4):364-6. doi: 10.1055/s-2001-14333. [PubMed: 11458458].
  • 14. Gobbi M, Moia M, Funicello M, Riva A, Morazzoni P, Mennini T. In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models. Planta Med. 2004;70(7):680-2. doi: 10.1055/s-2004-827194. [PubMed: 15303261].
  • 15. Heilmann J, Winkelmann K, Sticher O. Studies on the antioxidative activity of phloroglucinol derivatives isolated from hypericum species. Planta Med. 2003;69(3):202-6. doi: 10.1055/s-2003-38477. [PubMed: 12677521].
  • 16. Feisst C, Werz O. Suppression of receptor-mediated Ca2+ mobilization and functional leukocyte responses by hyperforin. Biochem Pharmacol. 2004;67(8):1531-9. doi: 10.1016/j.bcp.2003.12.020. [PubMed: 15041470].
  • 17. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329-42. doi: 10.1038/nri3661. [PubMed: 24751956].
  • 18. Matricon J, Barnich N, Ardid D. Immunopathogenesis of inflammatory bowel disease. Self Nonself. 2010;1(4):299-309. doi: 10.4161/self.1.4.13560. [PubMed: 21487504].
  • 19. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146(6):1489-99. doi: 10.1053/j.gastro.2014.02.009. [PubMed: 24560869].
  • 20. Sohrabpour AA, Malekzadeh R, Keshavarzian A. Current therapeutic approaches in inflammatory bowel disease. Curr Pharm Des. 2010;16(33):3668-83. [PubMed: 21128898].
  • 21. Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185-210. doi: 10.2147/DDDT.S11290. [PubMed: 21552489].
  • 22. Kalantari H, Dashtearjandi AA, Kalantar E. Genotoxicity study of Hypiran and Chamomilla herbal drugs determined by in vivo supervital micronucleus assay with mouse peripheral reticulocytes. Acta Biol Hung. 2009;60(2):177-83. doi: 10.1556/ABiol.60.2009.2.5. [PubMed: 19584027].
  • 23. Low D, Nguyen DD, Mizoguchi E. Animal models of ulcerative colitis and their application in drug research. Drug Des Devel Ther. 2013;7:1341-57. doi: 10.2147/DDDT.S40107. [PubMed: 24250223].
  • 24. Al-Rejaie SS, Abuohashish HM, Al-Enazi MM, Al-Assaf AH, Parmar MY, Ahmed MM. Protective effect of naringenin on acetic acid-induced ulcerative colitis in rats. World J Gastroenterol. 2013;19(34):5633-44. doi: 10.3748/wjg.v19.i34.5633. [PubMed: 24039355].
  • 25. Pulli B, Ali M, Forghani R, Schob S, Hsieh KL, Wojtkiewicz G, et al. Measuring myeloperoxidase activity in biological samples. PLoS One. 2013;8(7). e67976. doi: 10.1371/journal.pone.0067976. [PubMed: 23861842].
  • 26. Bryan NS, Grisham MB. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic Biol Med. 2007;43(5):645-57. doi: 10.1016/j.freeradbiomed.2007.04.026. [PubMed: 17664129].
  • 27. Al-Rejaie SS, Aleisa AM, Sayed-Ahmed MM, Al-Shabanah OA, Abuohashish HM, Ahmed MM, et al. Protective effect of rutin on the antioxidant genes expression in hypercholestrolemic male Westar rat. BMC Complement Altern Med. 2013;13:136. doi: 10.1186/1472-6882-13-136. [PubMed: 23773725].
  • 28. Gao Y, Huang Y, Zhao Y, Hu Y, Li Z, Guo Q, et al. LL202 protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting MAPK/AP-1 signaling. Oncotarget. 2016;7(39):63981-94. doi: 10.18632/oncotarget.11742. [PubMed: 27590510].
  • 29. Orsonneau JL, Douet P, Massoubre C, Lustenberger P, Bernard S. An improved pyrogallol red-molybdate method for determining total urinary protein. Clin Chem. 1989;35(11):2233-6. [PubMed: 2582622].
  • 30. Tahan G, Aytac E, Aytekin H, Gunduz F, Dogusoy G, Aydin S, et al. Vitamin E has a dual effect of anti-inflammatory and antioxidant activities in acetic acid-induced ulcerative colitis in rats. Can J Surg. 2011;54(5):333-8. doi: 10.1503/cjs.013610. [PubMed: 21933527].
  • 31. Sanei MH, Hadizadeh F, Adibi P, Alavi SA. Inflammatory cells' role in acetic acid-induced colitis. Adv Biomed Res. 2014;3:193. doi: 10.4103/2277-9175.140666. [PubMed: 25337523].
  • 32. Joshi R, Kumar S, Unnikrishnan M, Mukherjee T. Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: mechanistic aspects and antioxidant activity. Free Radic Res. 2005;39(11):1163-72. doi: 10.1080/10715760500177880. [PubMed: 16298742].
  • 33. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270(5234):286-90. [PubMed: 7569976].
  • 34. Tumen I, Akkol EK, Suntar I, Keles H. Wound repair and anti-inflammatory potential of essential oils from cones of Pinaceae: preclinical experimental research in animal models. J Ethnopharmacol. 2011;137(3):1215-20. doi: 10.1016/j.jep.2011.07.046. [PubMed: 21816214].
  • 35. Khan RA, Khan MR, Sahreen S. CCl4-induced hepatotoxicity: protective effect of rutin on p53, CYP2E1 and the antioxidative status in rat. BMC Complement Altern Med. 2012;12:178. doi: 10.1186/1472-6882-12-178. [PubMed: 23043521].
  • 36. Consalvi S, Biava M, Poce G. COX inhibitors: a patent review (2011 - 2014). Expert Opin Ther Pat. 2015;25(12):1357-71. doi: 10.1517/13543776.2015.1090973. [PubMed: 26566186].
  • 37. Albert D, Zundorf I, Dingermann T, Muller WE, Steinhilber D, Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol. 2002;64(12):1767-75. [PubMed: 12445866].
  • 38. Huang N, Rizshsky L, Hauck CC, Nikolau BJ, Murphy PA, Birt DF. The inhibition of lipopolysaccharide-induced macrophage inflammation by 4 compounds in Hypericum perforatum extract is partially dependent on the activation of SOCS3. Phytochemistry. 2012;76:106-16. doi: 10.1016/j.phytochem.2011.12.001. [PubMed: 22245632].
  • 39. Zhan X, Wang F, Bi Y, Ji B. Animal models of gastrointestinal and liver diseases. Animal models of acute and chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2016;311(3):G343-55. doi: 10.1152/ajpgi.00372.2015. [PubMed: 27418683].
  • 40. Cassano P, Bui E, Rogers AH, Walton ZE, Ross R, Zeng M, et al. Inflammatory cytokines in major depressive disorder: A case-control study. Aust N Z J Psychiatry. 2017;51(1):23-31. doi: 10.1177/0004867416652736. [PubMed: 27313138].
  • 41. Motlagh BM, Ahangaran NA, Froushani SM. Calcitriol modulates the effects of bone marrow-derived mesenchymal stem cells on macrophage functions. Iran J Basic Med Sci. 2015;18(7):672-6. [PubMed: 26351558].
  • 42. Kraus B, Wolff H, Elstner EF, Heilmann J. Hyperforin is a modulator of inducible nitric oxide synthase and phagocytosis in microglia and macrophages. Naunyn Schmiedebergs Arch Pharmacol. 2010;381(6):541-53. doi: 10.1007/s00210-010-0512-y. [PubMed: 20369228].
  • 43. Orcic DZ, Mimica-Dukic NM, Franciskovic MM, Petrovic SS, Jovin ED. Antioxidant activity relationship of phenolic compounds in Hypericum perforatum L. Chem Cent J. 2011;5:34. doi: 10.1186/1752-153X-5-34. [PubMed: 21702979].
  • 44. Fabia R, Ar'Rajab A, Johansson ML, Andersson R, Willen R, Jeppsson B, et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion. 1993;54(4):248-55. [PubMed: 8243838].
  • 45. Kedia S, Rampal R, Paul J, Ahuja V. Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India. J Gastroenterol. 2016;51(7):660-71. doi: 10.1007/s00535-016-1193-1. [PubMed: 26994772].
  • 46. Lucas Lopez R, Grande Burgos MJ, Galvez A, Perez Pulido R. The human gastrointestinal tract and oral microbiota in inflammatory bowel disease: a state of the science review. APMIS. 2017;125(1):3-10. doi: 10.1111/apm.12609. [PubMed: 27704622].
  • 47. Suchodolski JS, Jergens AE. Recent Advances and Understanding of Using Probiotic-Based Interventions to Restore Homeostasis of the Microbiome for the Prevention/Therapy of Bacterial Diseases. Microbiol Spectr. 2016;4(2). doi: 10.1128/microbiolspec.VMBF-0025-2015. [PubMed: 27227298].
  • 48. Suntar I, Oyardi O, Akkol EK, Ozcelik B. Antimicrobial effect of the extracts from Hypericum perforatum against oral bacteria and biofilm formation. Pharm Biol. 2016;54(6):1065-70. doi: 10.3109/13880209.2015.1102948. [PubMed: 26510970].
  • 49. Dost T, Ozkayran H, Gokalp F, Yenisey C, Birincioglu M. The effect of Hypericum perforatum (St. John's Wort) on experimental colitis in rat. Dig Dis Sci. 2009;54(6):1214-21. doi: 10.1007/s10620-008-0477-6. [PubMed: 18754092].
  • 50. TANIDEH N, NEMATOLLAHI SL, HOSSEINI SV, HOSSEINZADEH M, MEHRABANI D, SAFARPOUR A, et al. Use of of hypericum perforatum extract in treatment of acetic acid induced ulcerative colitis. Govaresh J. 2015;20:33-4.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments